Regulation of bone metabolism in immunosuppressant (FK506)-treated rats

Shiho Kirino, Jyoji Fukunaga, Shuji Ikegami, Hiroshi Tsuboi, Masataka Kimata, Naoki Nakata, Makoto Nakano, Takaaki Ueno, Nobuyoshi Mizukawa, Toshio Sugahara

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

After organ transplantation, severe osteoporosis is occasionally seen, and the use of immunosuppressants is thought to be one of the causes of such osteoporosis. In the present study, we investigated the effects of FK506 monotherapy on bones and determined the mechanism of onset of osteoporosis, both by assessing chronological changes in bone metabolism and by identifying factors that facilitate bone resorption. In 8-week-old male Sprague-Dawley rats, FK506 (1 mg/kg) was injected intraperitoneally every day for 5 weeks (FK506-treated group), and for comparison, physiological saline was administered in the same manner in a control group of rats. Serum and urine samples were collected at weeks 0, 1, 3, and 5 of administration. The femur and tibia were collected within 24 h of the final administration. When compared to the control group, findings on three-dimensional micro-computed tomography of the femur for the FK506-treated group showed a significant decrease in trabecular bone volume. The level of serum osteocalcin in the FK506-treated group at week 1 of administration was significantly higher than the control. Throughout the administration period, the sum of urinary pyridinoline (PYD) and deoxypyridinoline (Dpd) was significantly higher in the FK506-treated group. Of the various bone resorption factors tested, the level of serum parathyroid hormone (PTH) in the FK506-treated group was significantly higher than the control at week 3 of administration. The results of the present study confirmed that FK506 monotherapy in rats induced high-turnover osteoporosis. Soon after the start of FK506 administration, bone formation and resorption were elevated, and PTH appeared to have been involved in the maintenance of the elevated bone resorption.

Original languageEnglish
Pages (from-to)554-560
Number of pages7
JournalJournal of Bone and Mineral Metabolism
Volume22
Issue number6
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Tacrolimus
Immunosuppressive Agents
Bone and Bones
Osteoporosis
Bone Resorption
Parathyroid Hormone
Femur
Serum
Control Groups
Osteocalcin
Organ Transplantation
Tibia
Osteogenesis
Sprague Dawley Rats
Tomography
Maintenance
Urine

Keywords

  • Bone metabolism marker
  • Immunosuppressant
  • Osteoporosis

ASJC Scopus subject areas

  • Endocrinology

Cite this

Kirino, S., Fukunaga, J., Ikegami, S., Tsuboi, H., Kimata, M., Nakata, N., ... Sugahara, T. (2004). Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. Journal of Bone and Mineral Metabolism, 22(6), 554-560. https://doi.org/10.1007/s00774-004-0523-1

Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. / Kirino, Shiho; Fukunaga, Jyoji; Ikegami, Shuji; Tsuboi, Hiroshi; Kimata, Masataka; Nakata, Naoki; Nakano, Makoto; Ueno, Takaaki; Mizukawa, Nobuyoshi; Sugahara, Toshio.

In: Journal of Bone and Mineral Metabolism, Vol. 22, No. 6, 11.2004, p. 554-560.

Research output: Contribution to journalArticle

Kirino, S, Fukunaga, J, Ikegami, S, Tsuboi, H, Kimata, M, Nakata, N, Nakano, M, Ueno, T, Mizukawa, N & Sugahara, T 2004, 'Regulation of bone metabolism in immunosuppressant (FK506)-treated rats', Journal of Bone and Mineral Metabolism, vol. 22, no. 6, pp. 554-560. https://doi.org/10.1007/s00774-004-0523-1
Kirino, Shiho ; Fukunaga, Jyoji ; Ikegami, Shuji ; Tsuboi, Hiroshi ; Kimata, Masataka ; Nakata, Naoki ; Nakano, Makoto ; Ueno, Takaaki ; Mizukawa, Nobuyoshi ; Sugahara, Toshio. / Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. In: Journal of Bone and Mineral Metabolism. 2004 ; Vol. 22, No. 6. pp. 554-560.
@article{6b2efa054cea4ae79af57f7ac0b8a3dd,
title = "Regulation of bone metabolism in immunosuppressant (FK506)-treated rats",
abstract = "After organ transplantation, severe osteoporosis is occasionally seen, and the use of immunosuppressants is thought to be one of the causes of such osteoporosis. In the present study, we investigated the effects of FK506 monotherapy on bones and determined the mechanism of onset of osteoporosis, both by assessing chronological changes in bone metabolism and by identifying factors that facilitate bone resorption. In 8-week-old male Sprague-Dawley rats, FK506 (1 mg/kg) was injected intraperitoneally every day for 5 weeks (FK506-treated group), and for comparison, physiological saline was administered in the same manner in a control group of rats. Serum and urine samples were collected at weeks 0, 1, 3, and 5 of administration. The femur and tibia were collected within 24 h of the final administration. When compared to the control group, findings on three-dimensional micro-computed tomography of the femur for the FK506-treated group showed a significant decrease in trabecular bone volume. The level of serum osteocalcin in the FK506-treated group at week 1 of administration was significantly higher than the control. Throughout the administration period, the sum of urinary pyridinoline (PYD) and deoxypyridinoline (Dpd) was significantly higher in the FK506-treated group. Of the various bone resorption factors tested, the level of serum parathyroid hormone (PTH) in the FK506-treated group was significantly higher than the control at week 3 of administration. The results of the present study confirmed that FK506 monotherapy in rats induced high-turnover osteoporosis. Soon after the start of FK506 administration, bone formation and resorption were elevated, and PTH appeared to have been involved in the maintenance of the elevated bone resorption.",
keywords = "Bone metabolism marker, Immunosuppressant, Osteoporosis",
author = "Shiho Kirino and Jyoji Fukunaga and Shuji Ikegami and Hiroshi Tsuboi and Masataka Kimata and Naoki Nakata and Makoto Nakano and Takaaki Ueno and Nobuyoshi Mizukawa and Toshio Sugahara",
year = "2004",
month = "11",
doi = "10.1007/s00774-004-0523-1",
language = "English",
volume = "22",
pages = "554--560",
journal = "Journal of Bone and Mineral Metabolism",
issn = "0914-8779",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Regulation of bone metabolism in immunosuppressant (FK506)-treated rats

AU - Kirino, Shiho

AU - Fukunaga, Jyoji

AU - Ikegami, Shuji

AU - Tsuboi, Hiroshi

AU - Kimata, Masataka

AU - Nakata, Naoki

AU - Nakano, Makoto

AU - Ueno, Takaaki

AU - Mizukawa, Nobuyoshi

AU - Sugahara, Toshio

PY - 2004/11

Y1 - 2004/11

N2 - After organ transplantation, severe osteoporosis is occasionally seen, and the use of immunosuppressants is thought to be one of the causes of such osteoporosis. In the present study, we investigated the effects of FK506 monotherapy on bones and determined the mechanism of onset of osteoporosis, both by assessing chronological changes in bone metabolism and by identifying factors that facilitate bone resorption. In 8-week-old male Sprague-Dawley rats, FK506 (1 mg/kg) was injected intraperitoneally every day for 5 weeks (FK506-treated group), and for comparison, physiological saline was administered in the same manner in a control group of rats. Serum and urine samples were collected at weeks 0, 1, 3, and 5 of administration. The femur and tibia were collected within 24 h of the final administration. When compared to the control group, findings on three-dimensional micro-computed tomography of the femur for the FK506-treated group showed a significant decrease in trabecular bone volume. The level of serum osteocalcin in the FK506-treated group at week 1 of administration was significantly higher than the control. Throughout the administration period, the sum of urinary pyridinoline (PYD) and deoxypyridinoline (Dpd) was significantly higher in the FK506-treated group. Of the various bone resorption factors tested, the level of serum parathyroid hormone (PTH) in the FK506-treated group was significantly higher than the control at week 3 of administration. The results of the present study confirmed that FK506 monotherapy in rats induced high-turnover osteoporosis. Soon after the start of FK506 administration, bone formation and resorption were elevated, and PTH appeared to have been involved in the maintenance of the elevated bone resorption.

AB - After organ transplantation, severe osteoporosis is occasionally seen, and the use of immunosuppressants is thought to be one of the causes of such osteoporosis. In the present study, we investigated the effects of FK506 monotherapy on bones and determined the mechanism of onset of osteoporosis, both by assessing chronological changes in bone metabolism and by identifying factors that facilitate bone resorption. In 8-week-old male Sprague-Dawley rats, FK506 (1 mg/kg) was injected intraperitoneally every day for 5 weeks (FK506-treated group), and for comparison, physiological saline was administered in the same manner in a control group of rats. Serum and urine samples were collected at weeks 0, 1, 3, and 5 of administration. The femur and tibia were collected within 24 h of the final administration. When compared to the control group, findings on three-dimensional micro-computed tomography of the femur for the FK506-treated group showed a significant decrease in trabecular bone volume. The level of serum osteocalcin in the FK506-treated group at week 1 of administration was significantly higher than the control. Throughout the administration period, the sum of urinary pyridinoline (PYD) and deoxypyridinoline (Dpd) was significantly higher in the FK506-treated group. Of the various bone resorption factors tested, the level of serum parathyroid hormone (PTH) in the FK506-treated group was significantly higher than the control at week 3 of administration. The results of the present study confirmed that FK506 monotherapy in rats induced high-turnover osteoporosis. Soon after the start of FK506 administration, bone formation and resorption were elevated, and PTH appeared to have been involved in the maintenance of the elevated bone resorption.

KW - Bone metabolism marker

KW - Immunosuppressant

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=8744305772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8744305772&partnerID=8YFLogxK

U2 - 10.1007/s00774-004-0523-1

DO - 10.1007/s00774-004-0523-1

M3 - Article

VL - 22

SP - 554

EP - 560

JO - Journal of Bone and Mineral Metabolism

JF - Journal of Bone and Mineral Metabolism

SN - 0914-8779

IS - 6

ER -